Clinical Trials Finder
Independent ClinicalTrials.gov directory
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

ClinicalTrials.gov ID: NCT05855200

Public ClinicalTrials.gov record NCT05855200. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced May 10, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Study identification

NCT ID
NCT05855200
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
892 participants

Conditions and interventions

Interventions

  • CAPEOX Drug
  • Dostarlimab Biological
  • FOLFOX Drug

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2023
Primary completion
Mar 18, 2029
Completion
Mar 26, 2031
Last update posted
Jan 22, 2026

2023 – 2031

United States locations

U.S. sites
49
U.S. states
25
U.S. cities
34
Facility City State ZIP Site status
GSK Investigational Site Tucson Arizona 85715 Recruiting
GSK Investigational Site Los Angeles California 90027 Recruiting
GSK Investigational Site New Haven Connecticut 06520 Recruiting
GSK Investigational Site Washington D.C. District of Columbia 20010 Withdrawn
GSK Investigational Site Deerfield Beach Florida 33064 Withdrawn
GSK Investigational Site Fort Lauderdale Florida 33316 Withdrawn
GSK Investigational Site Marietta Georgia 30060 Withdrawn
GSK Investigational Site Chicago Illinois 60611 Recruiting
GSK Investigational Site Chicago Illinois 60612 Recruiting
GSK Investigational Site Chicago Illinois 60637 Withdrawn
GSK Investigational Site Naperville Illinois 60126 Recruiting
GSK Investigational Site Naperville Illinois 60540 Recruiting
GSK Investigational Site Westwood Kansas 66205 Recruiting
GSK Investigational Site Lexington Kentucky 40503 Withdrawn
GSK Investigational Site Louisville Kentucky 40206 Withdrawn
GSK Investigational Site Baton Rouge Louisiana 70809 Withdrawn
GSK Investigational Site Bethesda Maryland 20817 Recruiting
GSK Investigational Site Ann Arbor Michigan 48109 Withdrawn
GSK Investigational Site Detroit Michigan 48202 Recruiting
GSK Investigational Site Minneapolis Minnesota 55455 Recruiting
GSK Investigational Site Joplin Missouri 64804 Withdrawn
GSK Investigational Site St Louis Missouri 63128 Withdrawn
GSK Investigational Site St Louis Missouri 63141 Withdrawn
GSK Investigational Site Grand Island Nebraska 68803 Recruiting
GSK Investigational Site Omaha Nebraska 68130 Recruiting
GSK Investigational Site Omaha Nebraska 68198 Withdrawn
GSK Investigational Site Lebanon New Hampshire 03756 Withdrawn
GSK Investigational Site New York New York 10028 Recruiting
GSK Investigational Site New York New York 10469 Recruiting
GSK Investigational Site New York New York 11042 Recruiting
GSK Investigational Site New York New York 11967 Recruiting
GSK Investigational Site The Bronx New York 10461 Recruiting
GSK Investigational Site Durham North Carolina 27710 Recruiting
GSK Investigational Site Akron Ohio 44304 Recruiting
GSK Investigational Site Cincinnati Ohio 45220 Recruiting
GSK Investigational Site Cleveland Ohio 44111 Withdrawn
GSK Investigational Site Cleveland Ohio 44142 Withdrawn
GSK Investigational Site Cleveland Ohio 44196 Withdrawn
GSK Investigational Site Oklahoma City Oklahoma 73104 Withdrawn
GSK Investigational Site Oklahoma City Oklahoma 73120 Withdrawn
GSK Investigational Site Pittsburgh Pennsylvania 15212 Withdrawn
GSK Investigational Site Sioux Falls South Dakota 57078 Recruiting
GSK Investigational Site Sioux Falls South Dakota 57105 Recruiting
GSK Investigational Site Sioux Falls South Dakota 57401 Recruiting
GSK Investigational Site Sioux Falls South Dakota 57501 Recruiting
GSK Investigational Site Dallas Texas 75235 Withdrawn
GSK Investigational Site Dallas Texas 75390 Completed
GSK Investigational Site Richmond Virginia 23229 Recruiting
GSK Investigational Site Appleton Wisconsin 54911 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 214 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05855200, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 22, 2026 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05855200 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →